MALIN CORPORATION PL

MLC
Real-time Quote. Real-time  - 12/02 11:30:14 am
7EUR +2.94%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals
Malin Corporation plc is an Ireland-based global life sciences company. The Company's businesses include Altan, which is an injectable drug company; AN2H Discovery Limited, which focuses on designing novel small molecule therapeutics; Emba Medical Limited, which offers vascular embolization system; Emba Neuro Limited; Hatteras Venture Partners (HVP), which is a life sciences company; Immunocore, which is a biotechnology company; Jaan Health, which is a healthcare mobile technology company; Melinta Therapeutics, Inc.; Novan, Inc., which is a clinical stage company; Poseida Therapeutics, Inc., which is a human therapeutics company, and Viamet Pharmaceuticals, Inc., which is a drug discovery company. The Company operates through subsidiaries, and focuses on various therapeutic areas, including dermatology, anti-infective, pain, immunology, oncology, neurology, anatomy and other areas.

Number of employees : 255 people.
Sales per Business
20192020
Novel Therapeutic Solutions34.90100%41.00100%
EUR in Million
Sales per region
20192020
Spain17.6050.4%19.4047.3%
European Union (Excluding Spain)7.2020.6%11.9029%
Rest of World10.1028.9%9.7023.7%
EUR in Million
Managers
Name Title
Darragh Lyons Chief Executive Officer & Executive Director
Pat Jennings Chief Financial Officer
William Francis Daniel Non-Executive Chairman
Ita Finegan Chief Administrator
Jean-Michel Yves Sylvain Cossery Independent Non-Executive Director
Rudy Mareel Lead Independent Non-Executive Director
Kirsten Aarup Drejer Independent Non-Executive Director
Luke Corning Non-Executive Director
Jessica Bergin Head-Investor Relations
Fiona Dunlevy Secretary
Shareholders
Name Equities %
Pentwater Capital Management LP 12,472,982 28.6%
Reedy Creek Investments LLC 5,380,263 12.3%
The Pension Protection Fund 5,058,642 11.6%
National Treasury Management Agency (Invt Mgmt) 5,000,000 11.5%
Peter D. Löscher 2,173,240 4.98%
UBS Asset Management Switzerland AG 1,309,038 3.00%
CRUX Asset Management Ltd. 764,677 1.75%
KBI Global Investors Ltd. 217,468 0.50%
Medical Strategy GmbH 125,716 0.29%
Invesco Capital Management LLC 81,766 0.19%
Company contact information
The Lennox Building 50 Richmond Street South
IE-D02 FK02 Dublin, Leinster 2


Phone : +353 (0)1 901 5700
Fax : +353 (0)1 901 5701
web site : http://www.malinplc.com
Markets and indexes
- Euronext Growth Dublin
- ISEQ All Share / Euronext Growth All-Share, ISEQ Small, PEA
Stock Exchange Codes
- Bloomberg Code :  MLC:ID
- Reuters Code :  MLC.I
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
MALIN CORPORATION PLC0.00%336
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
PFIZER, INC.48.55%306 912
NOVO NORDISK A/S66.91%247 444
ELI LILLY AND COMPANY47.55%225 859
ABBVIE INC.8.18%204 915
MERCK & CO., INC.-9.00%188 031
NOVARTIS AG-11.25%180 565
ASTRAZENECA PLC13.52%171 528
SANOFI9.07%122 030
BRISTOL-MYERS SQUIBB COMPANY-11.41%121 969
AMGEN INC.-13.50%113 104
GLAXOSMITHKLINE PLC14.84%102 790
CHUGAI PHARMACEUTICAL CO., LTD.-33.96%52 902
JIANGSU HENGRUI MEDICINE CO., LTD.-45.63%50 537
BAYER AG-5.78%50 479
DAIICHI SANKYO COMPANY, LIMITED-19.82%48 101
TAKEDA PHARMACEUTICAL COMPANY LIMITED-19.76%41 547
ASTELLAS PHARMA INC.10.10%28 790
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY44.16%23 918
Brand Portfolio
» More brands of Malin Corporation Plc